Skip to main content
Premium Trial:

Request an Annual Quote

Allegro Dx Licenses IP from BU, University of Utah Foundation for Lung Cancer Test


By Justin Petrone

Allegro Diagnostics this week announced an exclusive license agreement with Boston University and the University of Utah Foundation for intellectual property related to its molecular testing platform.

Called BronchoGen, Allegro's test is manufactured by Affymetrix, and relies on an 80-gene biomarker signature to detect and rule out the presence of lung cancer using histologically normal large-airway epithelial cells obtained at bronchoscopy from smokers suspected to have the disease. The company believes its test can be used in combination with standard bronchoscopy to achieve a diagnosis.

Allegro CEO Mike Webb said in a statement that the licensing agreement will support the "continued advancement" of BronchoGen, including a planned commercial launch in the first half of 2012. Webb was named president and CEO of the Maynard, Mass.-based firm earlier this month (BAN 6/21/2011).

Avrum Spira, director of the Clinical and Translational Science Institute at BU, said in a statement that BU was "pleased" to license technology that "may enable the early detection of lung cancer." Spira co-founded Allegro with fellow BU investigator Jerome Brody in 2006. Dan Rippy, the firm's previous CEO, told BioArray News last year that the company hoped to the debut test in 2010 (BAN 1/5/2010).

Financial terms of the licensing agreement were not disclosed.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.